[Clinical effects of extracorporeal shock wave combined with complex decongestive therapy in the treatment of lower limb lymphedema after cervical cancer surgery]

Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2025 Jun 20;41(6):543-551. doi: 10.3760/cma.j.cn501225-20250205-00051.
[Article in Chinese]

Abstract

Objective: To explore the clinical effects of extracorporeal shock wave therapy (ESWT) combined with complex decongestive therapy (CDT) in the treatment of lower limb lymphedema after cervical cancer surgery. Methods: This study was a prospective randomized controlled trial. From April 2023 to December 2024, 64 patients were admitted to the Department of Oncology Rehabilitation of Nan'ao People's Hospital of Dapeng New District of Shenzhen. All patients were female, aged 33-75 years. The patients were divided into control group treated with CDT alone and combined treatment group treated with ESWT and CDT according to the random number table method, with 32 patients in each group. Four patients withdrew in the research process, and 30 patients were included in each group finally. Before treatment and at the end of 4 weeks of treatment (hereinafter referred to as after treatment), the skin stiffness was measured using a portable MyotonPRO device at the superficial projection position of vastus lateralis, vastus medialis, vastus intermedius, medial gastrocnemius, and lateral gastrocnemius to reflect the degree of skin fibrosis of lower limb, the circumferences were measured at the mid-knee, 10 cm and 20 cm above the superior patellar border, and the mid-ankle, 10 cm and 20 cm below the inferior patellar border to reflect the severity degree of edema of lower limb, the life quality was scored using the simplified Chinese version of the lower limb lymphedema functioning, disability, and health questionnaire (Lymph-ICF-LL), and the pain intensity was scored using the visual analogue scale (VAS). The differences of the above indexes were calculated between before and after treatment. Results: The skin stiffness at the superficial projection position of vastus lateralis, vastus medialis, vastus intermedius, medial gastrocnemius, and lateral gastrocnemius of patients in combined treatment group after treatment was significantly smaller than that in control group (with t values of 2.78, 2.04, 3.12, 2.01, and 2.35, respectively, P<0.05). The differences in skin stiffness between before and after treatment at the superficial projection position of the above-mentioned muscles of patients in combined treatment group was (65±23), (24±8), (25±8), (65±27), and (69±34) N/m, respectively, which were significantly larger than (49±23), (16±19), (8±9), (45±39), and (43±42) N/m in control group (with t values of -2.75 -2.35, -7.47, -2.33, and -2.64, respectively, P<0.05), and the mean differences between groups (95% confidence intervals) were 16 (5 to 28), 9 (1 to 17), 17 (12 to 21), 20 (3 to 36), and 26 (4 to 49) N/m, respectively. The circumferences at 10 cm and 20 cm below the inferior patellar border, mid-knee, and 10 cm and 20 cm above the superior patellar border of patients in combined treatment group after treatment were significantly smaller than those in control group (with t values of -2.41, -2.49, -2.44, -2.21, and -2.36, respectively, P<0.05). The circumference differences between before and after treatment at the above-mentioned locations of patients in combined treatment group were significantly larger than those in control group (with t values of 2.21, 3.62, 3.35, 4.14, and 3.89, respectively, P<0.05), and the mean differences between groups (95% confidence intervals) were 2.3 (0.1 to 4.6), 2.4 (1.0 to 3.8), 2.1 (0.8 to 3.4), 3.5 (1.6 to 5.4), and 3.4 (1.5 to 5.2) cm, respectively. The VAS scores of lower limb and the total Lymph-ICF-LL scores of patients in combined treatment group after treatment were significantly lower than those in control group (with t values of -2.46 and -2.63, respectively, P<0.05); the differences of VAS scores of lower limb and the total Lymph-ICF-LL scores between before and after treatment of patients in combined treatment group were significantly higher than those in control group (with t values of 2.34 and 3.32, respectively, P<0.05), and the mean differences between groups (95% confidence intervals) were 0.5 (0 to 0.9) and 6 (2 to 9), respectively. Conclusions: Combined application of ESWT and CDT shows superior efficacy in alleviating lower limb lymphedema and skin fibrosis after cervical cancer surgery, and can relieve pain and improve patients' quality of life.

目的: 探讨体外冲击波疗法联合综合消肿治疗对宫颈癌术后下肢淋巴水肿的临床疗效。 方法: 该研究为前瞻性随机对照试验。2023年4月—2024年12月,深圳市大鹏新区南澳人民医院肿瘤康复科收治64例符合入选标准的宫颈癌术后下肢淋巴水肿患者,患者均为女性,年龄33~75岁。将患者按随机数字表法分为仅进行综合消肿治疗的对照组及进行体外冲击波疗法联合综合消肿治疗的联合治疗组,每组32例。研究过程中4例患者退出研究,最终每组纳入30例。于治疗前及4周治疗结束时(下称治疗后),采用便携式MyotonPRO仪测量股外侧肌、股内侧肌、股中间肌、腓肠肌内侧头、腓肠肌外侧头体表投射位置的皮肤硬度,以反映下肢皮肤纤维化程度;测量膝中、髌骨上缘上10 cm、髌骨上缘上20 cm、踝中、髌骨下缘下20 cm、髌骨下缘下10 cm处的周径,以反映下肢水肿程度;采用简体中文版下肢淋巴水肿功能、残疾与健康问卷(Lymph-ICF-LL)进行生活质量评分,采用视觉模拟评分法(VAS)进行下肢疼痛程度评分。计算上述指标治疗前后差值。 结果: 联合治疗组患者治疗后股外侧肌、股中间肌、股内侧肌、腓肠肌内侧头、腓肠肌外侧头体表投射位置的皮肤硬度均明显小于对照组(t值分别为2.78、2.04、3.12、2.01、2.35,P<0.05);联合治疗组患者治疗前后以上肌肉体表投射位置的皮肤硬度差值分别为(65±23)、(24±8)、(25±8)、(65±27)、(69±34)N/m,均明显大于对照组的(49±23)、(16±19)、(8±9)、(45±39)、(43±42)N/m(t值分别为-2.75、-2.35、-7.47、-2.33、-2.64,P<0.05),组间均数差值(95%置信区间)分别为16(5~28)、9(1~17)、17(12~21)、20(3~36)、26(4~49)N/m。联合治疗组患者治疗后髌骨下缘下20 cm、髌骨下缘下10 cm、膝中、髌骨上缘上10 cm、髌骨上缘上20 cm处的周径均明显小于对照组(t值分别为-2.41、-2.49、-2.44、-2.21、-2.36,P<0.05);联合治疗组患者治疗前后以上位置周径差值均明显大于对照组(t值分别为2.21、3.62、3.35、4.14、3.89,P<0.05),组间均数差值(95%置信区间)分别为2.3(0.1~4.6)、2.4(1.0~3.8)、2.1(0.8~3.4)、3.5(1.6~5.4)、3.4(1.5~5.2)cm。联合治疗组患者治疗后下肢VAS评分和Lymph-ICF-LL总得分均明显低于对照组(t值分别为-2.46、-2.63,P<0.05);联合治疗组患者治疗前后下肢VAS评分和Lymph-ICF-LL总得分差值均明显高于对照组(t值分别为2.34、3.32,P<0.05),组间均数差值(95%置信区间)分别为0.5(0~0.9)、6(2~9)分。 结论: 体外冲击波疗法联合综合消肿治疗在改善宫颈癌术后下肢淋巴水肿和皮肤纤维化方面具有显著疗效,且能缓解疼痛,提高患者生活质量。.

Publication types

  • Randomized Controlled Trial
  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Combined Modality Therapy
  • Extracorporeal Shockwave Therapy* / methods
  • Female
  • Humans
  • Lower Extremity
  • Lymphedema* / etiology
  • Lymphedema* / therapy
  • Middle Aged
  • Postoperative Complications* / therapy
  • Prospective Studies
  • Quality of Life
  • Treatment Outcome
  • Uterine Cervical Neoplasms* / surgery